Cost-offset analysis: Bimatoprost versus other prostaglandin analogues in open-angle glaucoma

American Journal of Managed Care

Volumn 17, Issue 9, 2011, Pages

  Berenson, Karina L ^a   Kymes, Steven ^b   Hollander, David A ^c   Fiscella, Richard ^d   Burk, Caroline ^e   Patel, Vaishali D ^c  

^a Analytica International   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALLERGAN INC   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Outcomes Research Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE COURSE; DRUG COST; DRUG MARKETING; DRUG SUBSTITUTION; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MANAGED CARE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TRABECULOPLASTY;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HUMANS; INTRAOCULAR PRESSURE; MANAGED CARE PROGRAMS; MARKOV CHAINS; MODELS, ECONOMIC; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC; TIME FACTORS; UNITED STATES;

EID: 80053041576     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Prevent Blindness America. Americans affected by age-related eye disease: vision problems in the US. Prevalence of adult vision impairment and age-related eye disease in America. http://www.prevent-blindness. org/sites/default/files/national/documents/glaucoma.pdf. Accessed June 12, 2008.
2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
3. Kymes SM, Burk C, Feinman T, Williams JM, Hollander DA. Demonstration of an online tool to assist managed care formulary evidence-based decision making: a meta-analysis of topical prostaglandin analog efficacy. Ther Clin Risk Manage. 2011;7:283-290.
4. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E; Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol.2003;121(1):48- 56.
5. Shields M, ed. An overview of glaucoma. In: Textbook of Glaucoma. 4th ed. Baltimore: Williams & Wilkins; 1998:1-2.
6. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States [published correction appears in Arch Ophthalmol. 2007;125(9):1304]. Arch Ophthalmol. 2006;124(12):1754-1760.
7. Kymes SM, Plotzke MR, Li JZ, Nichol MB, Wu J, Fain J. The increased cost of medical services for people diagnosed with primary open-angle glaucoma: a decision analytic approach. Am J Ophthalmol. 2010;150(1):74-81.
8. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol. 2006;124(1):12-19. (Pubitemid 43063883)
9. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19-24. (Pubitemid 32037003)
10. Beers MH, Berkow R, eds. Glaucoma. In: The Merck Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999.
11. Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703. (Pubitemid 36457976)
12. Netland PA, Landry T, Sullivan EK, et al; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 132(4):472-484. (Pubitemid 32904567)
13. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(suppl 4):S353-S360.
14. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y; Bimatoprost- Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370-1373. (Pubitemid 44702062)
15. Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112(2):262-266. (Pubitemid 40202562)
16. Choplin N, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/ Latanoprost Study Group. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49(suppl 1):S19-S25.
17. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM; Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110-121.
18. Kammer J, Katzman B, Ackerman S, Hollander D. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomized, masked-evaluator, multicenter study. Br J Ophthalmol. 2010;94(1):74-99.
19. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM; Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55-63. (Pubitemid 36020425)
20. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM; Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(suppl 1):S26-S35.
21. Bacharach J, Schenker HI, Caprioloi J, Liu C, Batoosingh AL. Masked, randomized, parallel comparison of IOP-lowering efficacy after switching to bimatoprost 0.03% vs continuing with latanoprost 0.005%. Presented at: 19th Annual Meeting of the American Glaucoma Society (AGS); March 2009; San Diego, CA.
22. Casson RJ, Liu L, Graham SL, et al. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. J Glaucoma. 2009;18(8): 582-588.
23. Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49 (suppl 1):S12-S18. (Pubitemid 38317483)
24. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17(8):667-673.
25. Law SK, Song BJ, Fang E, Caprioli J. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology. 2005;112(12): 2123-2130. (Pubitemid 41720990)
26. Kumar RS, Istiantoro VW, Hoh ST, Ho CL, Oen FT, Aung T. Efficacy and safety of a systematic switch from latanoprost to travoprost in patients with glaucoma. J Glaucoma. 2007;16(7):606-609. (Pubitemid 350307612)
27. McKinley SH, Singh R, Chang PT, Gross RL, Orengo-Nania S. Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic. J Ocul Pharmacol Ther. 2009;25(2):153-157.
28. Chauhan BC, Mikelberg FS, Balaszi AG, LeBlanc RP, Lesk MR, Trope GE; Canadian Glaucoma Study Group. Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma [published correction appears in Arch Ophthalmol. 2008;126(10):1364]. Arch Ophthalmol. 2008;126(8):1030-1036.
29. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429-440.
30. Friedman DS, Wolfs RC, O'Colmain BJ, et al; Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532-538.
31. LeapFrogRx. TRx Glauc vs PGA. Excel file. 2009. Data on file at Allergan, Inc.
32. LeapFrogRx. LUMIGAN® August Payer Analysis. PowerPoint Presentation. Oct 25, 2009. Data on file at Allergan, Inc.
33. Foundation for Managed Care Pharmacy. The AMCP Format for Formulary Submissions, Version 3.0. http://www.amcp.org/FmcpCategory. aspx?id=9166. Published October 2009. Accessed August 9, 2011.
34. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 1992;33(7):2224-2228.
35. LUMIGAN [prescribing information]. Irvine, CA: Allergen Inc; 2006.
36. Simmons ST, Bernstein P, Hollander DA. A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost. Am J Ophthalmol. 2008;146(3):473-477.
37. Health Strategies Group. Health Plan Industry Trends: Spring 2009. Lambertville, NJ: Health Strategies Group; 2009.
38. Varma R, Hwang LJ, Grunden JW, Bean GW. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials. Am J Ophthalmol. 2008;145(2): 336-342.
39. Hong S, Seong GJ, Hong YJ. Long-term intraocular pressure fluctuation and progressive visual field deterioration in patients with glaucoma and low intraocular pressures after a triple procedure. Arch Ophthalmol. 2007;125(8):1010-1013. (Pubitemid 47258028)
40. Berenson K, Kymes S, Walt JG, Siegartel LR. The relationship of mean deviation scores and resource utilization among patients with glaucoma: a retrospective United States and European chart review analysis. J Glaucoma. 2009;18(5):390-394.
41. Lee PP, Kelly SP, Mills RP, et al; Costs of Glaucoma Study Group. Glaucoma in the United States and Europe: predicting costs and surgical rates based upon stage of disease. J Glaucoma. 2007;16(5): 471-478. (Pubitemid 47263050)
42. MAG Mutual Healthcare Solutions, Inc. 2008 Physician's Fee and Coding Guide. http://www.coderscentral.com/08-fee-FG.htm. Accessed August 9, 2011.
43. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006;141(6):997-1008.
44. Gold M, Siegel J, Russell L, Weinsten M. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
45. Wolters Kluwer Health, Medi-Span. PC price check, data pulled Mar 29, 2011. http://www.medi-span.com/drug-pricing-analysis-pricerx.aspx.
46. Wolters Kluwer Health, Medi-Span. Price Alert: The latest price changes on leading Rx and OTC products. Apr 15, 2011;23(4).
47. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266(3):369-374.
48. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology. 1992;99(10):1499-1504.
49. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology. 1996;103(10):1661-1669. (Pubitemid 26357144)
50. Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Arch Ophthalmol. 2001;119(12):1819-1826. (Pubitemid 33139614)
51. Wolfs RC, Borger PH, Ramrattan RS, et al. Changing views on open-angle glaucoma: definitions and prevalences-The Rotterdam Study. Invest Ophthalmol Vis Sci. 2000;41(11):3309-3321.
52. Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology. 1998;105(4):733-739. (Pubitemid 28180227)